We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
WuXi Biologics, Prima Signs MOU
News

WuXi Biologics, Prima Signs MOU

WuXi Biologics, Prima Signs MOU
News

WuXi Biologics, Prima Signs MOU

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "WuXi Biologics, Prima Signs MOU"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

WuXi Biologics and Prima Biomed Ltd have announced that a non-binding MOU was signed to form a strategic biologics development and manufacturing partnership. Under the partnership, WuXi Biologics will be the exclusive clinical manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong Kong where rights are retained by Prima's development partner in China, Eddingpharm.

WuXi Biologics will also be Prima's preferred partner to manufacture potential new products. IMP321, a first-in-class soluble LAG-3 Ig fusion protein and an APC activator boosting T cell responses for cancer chemo-immunotherapy is currently in Phase II trials in Europe.

CEO of Prima BioMed, Mr. Marc Voigt said, "Securing the future supply of IMP321 is a key component of our commercial development strategy. WuXi Biologics have consistently delivered the highest quality materials for our clinical trials. This MOU further strengthens our strategic partnership."

"We are honored to play a critical role to enable biotech and pharma companies to realize commercialization via WuXi's innovative biomanufacturing network based on state-of-the-art disposable manufacturing technology," said Dr. Chris Chen, CEO of WuXi Biologics, "WuXi Biologics is committed to producing the highest quality product to enable robust global supply of this potential biologics to patients worldwide."

Source: Story from WuXi Biologics. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.

Advertisement